title: Prognostic Significance of Pre-treatment Serum C-Reactive Protein Level in Patients with Adenocarcinoma of the Uterine Cervix.
abstract: To evaluate pre-treatment serum C-reactive protein (CRP) level as a prognostic parameter in patients with adenocarcinoma of the uterine cervix.
  
  
  
  Pre-treatment CRP levels were analyzed to determine potential associations with clinicopathological parameters and to assess prognostic value in 46 patients with sole adenocarcinoma of the uterine cervix.
  
  
  
  The mean (±SD) pre-treatment serum CRP level was 5.82 (7.21) mg/l. Serum CRP concentration significantly correlated positively with age at diagnosis (p=0.001), lymphovascular space invasion (p=0.0026), recurrent disease (p=0.0001) and International Federation of Gynecology and Obstetrics (FIGO) stage (p=0.0002). In multivariate Cox regression models with age, FIGO stage, histological grade and lymph node status, elevated CRP and cancer antigen 125 levels were associated with shortened survival (p<0.05). Overall 5-year survival rate of patients with pre-treatment serum CRP level <5.0 mg/l was 100% compared to 46.9% for patients with pre-treatment CRP level ≥5.0 mg/l.
  
  
  
  Serum CRP level can be seen as an additional independent prognostic parameter in patients with the rare histological subtype adenocarcinoma of the uterine cervix.
authors.affiliation: Department of General Gynaecology and Gynaecologic Oncology, Medical University of Vienna, Vienna, Austria Barbara.Bodner-Adler@meduniwien.ac.at.
authors.forename: Barbara
authors.initials: B
authors.lastname: Bodner-Adler
authors.affiliation: Department of Anaesthesiology, Medical University of Vienna, Vienna, Austria.
authors.forename: Oliver
authors.initials: O
authors.lastname: Kimberger
authors.affiliation: Department of General Gynaecology and Gynaecologic Oncology, Medical University of Vienna, Vienna, Austria.
authors.forename: Cora
authors.initials: C
authors.lastname: Schneidinger
authors.affiliation: Department of General Gynaecology and Gynaecologic Oncology, Medical University of Vienna, Vienna, Austria.
authors.forename: Heinz
authors.initials: H
authors.lastname: Kölbl
authors.affiliation: Department of General Gynaecology and Gynaecologic Oncology, Medical University of Vienna, Vienna, Austria.
authors.forename: Klaus
authors.initials: K
authors.lastname: Bodner
mesh_terms: D000230:Adenocarcinoma / Q000097:blood* / Q000473:pathology; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D002097:C-Reactive Protein / Q000378:metabolism*; D002584:Cervix Uteri / Q000378:metabolism / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D002583:Uterine Cervical Neoplasms / Q000097:blood* / Q000473:pathology / Q000628:therapy
chemical_list: D014408:Biomarkers, Tumor; D002097:C-Reactive Protein
keywords: Pre-treatment C-reactive protein level; adenocarcinoma of uterine cervix; prognosticators